Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PoliovacSin is a specialized biotechnology entity focused on the production and distribution of polio vaccines, specifically the Inactivated Poliovirus Vaccine (IPV). The company operates as a key supplier in international immunization programs, often collaborating with global health organizations to ensure the availability of high-quality vaccines in regions transitioning from oral to inactivated polio vaccines. Its primary product, PoliovacSin, is an injectable vaccine containing inactivated types 1, 2, and 3 of the poliovirus. The company plays a critical role in the Global Polio Eradication Initiative by providing stable and effective vaccine supplies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PoliovacSin.